Paul Tudor Jones Ambrx Biopharma Inc. Transaction History

Tudor Investment Corp Et Al

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$1.06 - $2.96 $2,912 - $8,134	-2,748 Reduced 14.42%	16,315 $18,000
Q2 2022 Aug 15, 2022	SELL	$2.53 - $4.35 $2,732 - $4,698	-1,080 Reduced 5.36%	19,063 $51,000
Q3 2021 Nov 15, 2021	SELL	$13.31 - $22.53 $530,496 - $897,978	-39,857 Reduced 66.43%	20,143 $272,000
Q2 2021 Aug 16, 2021	BUY	$15.95 - $19.6 $957,000 - $1.18 Million	60,000 New	60,000 $1.18 Million

31.2K

Ticker AMAM
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,618,400
Market Cap $1.08B
Description
Ambrx Biopharma Inc., a clinical-stage biologics company, discovers and develops engineered precision biologics using its proprietary expanded genetic code technology platform. Its lead product candidate is ARX788, an anti-HER2 antibody-drug conjugate (ADC), which is investigated in various clinical trials for the treatment of breast cancer, gas...

Get notified when there are updates to the investment portfolio of Tudor Investment Corp Et Al, based on Form 13F filings with the SEC.

Stay updated on Tudor Investment Corp Et Al and Paul Tudor Jones with notifications on news.